|
|
-->
On November 16, 2006, the U.S. Food and Drug Administration (FDA) approved Herceptin® (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide and paclitaxel, for the adjuvant treatment of HER2-positive, node-positive breast cancer. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment — surgery with or without radiation therapy — with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.
|
| |
| |
| |
|
|
|
-->
On November 9, Genentech and Tanox announced plans for Genentech to acquire Tanox, a biotechnology company specializing in the discovery and development of biotherapeutics based on monoclonal antibody technology, for $20 per share for a total cash value of approximately $919 million. Genentech and Tanox have been working together in collaboration with Novartis since 1996 to develop and commercialize Xolair® (Omalizumab).
|
| |
| |
| |
| |
|
|
|
|
|
|
Event:
|
2006 Credit Suisse Health Care Conference
|
Date:
|
11/16/2006
|
Time:
|
9:30 AM
PT
|
|
|
Access Archived Webcast
|
|
|
|
Thursday, Nov 16, 2006
FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
|
Learn about Genentech's management team.
Visit Genentech's Newsroom, where reporters can find everything they need in one place.
|
|